Oral Delivery of Therapeutic Proteins and Peptides: An Overview of Current Technologies and Recommendations for Bridging from Approved Intravenous or Subcutaneous Administration to Novel Oral Regimens

Drug Research

Volumn 66, Issue 3, 2015, Pages 113-120

  Philippart, M ^a   Schmidt, J ^b   Bittner, B ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

bortezomib; monoclonal antibody; pharmacokinetics; rituximab; tocilizumab; trastuzumab

Indexed keywords

BORTEZOMIB; PEPTIDE; PROTEIN; RITUXIMAB; THERAPEUTIC PROTEIN; TOCILIZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME INHIBITION; PHARMACODYNAMICS; SYSTEMIC CIRCULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, SUBCUTANEOUS; PEPTIDES; PROTEINS;

EID: 84960093781     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0035-1559654     Document Type: Article

References (79)

1. Carter P. J. Introduction to current and future protein therapeutics: A protein engineering perspective. Exp Cell Res: 2011; 317 1261 1269
2. Hamman J. H., Enslin G. M., Kotze A. F. Oral delivery of peptide drugs: Barriers and developments. BioDrugs: 2005; 19 165 177
3. Ratnaparkhi M. P., Chaudhari S. P., Pandya V. A. Peptides and proteins in pharmaceuticals. Int J Curr Pharmaceut Res: 2011; 3 1 9
4. Leader B., Baca Q. J., Golan D. E. Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discov: 2008; 7 21 39
5. Yun Y., Cho Y. W., Park K. Nanoparticles for oral delivery: Targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev: 2013; 65 822 832
6. Park K., Kwon I. C., Park K. Oral protein delivery: Current status and future prospect. React Funct Polym: 2011; 71 280 287
7. Renukuntla J., Vadlapudi A. D., Patel A. et al. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm: 2013; 447 75 93
8. Pivot X., Gligorov J., Müller V. et al. PrefHer Study Group Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): An open-label randomised study. Lancet Oncol: 2013; 14 962 970
9. Hourcade-Potelleret F., Lemenuel-Diot A., McIntyre C. et al. Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab. CPT Pharmacometrics Syst Pharmacol: 2014; 3 e87
10. ®): A UK Time and Motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer. Adv Breast Can Res: 2013; 2 133 140
11. Bittner B., Richter W. F., Hourcade-Potelleret F. et al. Development of a subcutaneous formulation for trastuzumab-nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung: 2012; 62 401 409
12. Bittner B., Richter W. F., Hourcade-Potelleret F. et al. Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. Drug Res (Stuttg): 2014; 64 569 575
13. Gupta S., Jain A., Chakraborty M. et al. Oral delivery of therapeutic proteins and peptides: A review on recent developments. Drug Deliv: 2013; 20 237 246
14. Fasano A. Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol: 1998; 16 152 157
15. Barclay N., Tarallo M., Hendrikx T. et al. Patient preference for oral versus injectable and intravenous methods of treatment for rheumatoid arthritis. Poster presented at the 16th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR-EU); November 2-6: 2013; Dublin, Ireland
16. Borner M. M., Schoffski P., de Wit R. et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer: 2002; 38 349 358
17. Dibonaventura M. D., Wagner J. S., Girman C. J. et al. Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication. Patient Prefer Adherence: 2010; 4 397 406
18. Melmed S., Popovic V., Bidlingmaier M. et al. Safety and efficacy of oral octreotide in acromegaly: Results of a multicenter phase III trial. J Clin Endocrinol Metab: 2015; 100 1699 1708
19. Binkley N., Bolognese M., Sidorowicz-Bialynicka A. et al. Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res: 2012; 27 1821 1829
20. Lee VH L., Dodda-Kashi S., Grass G. M. et al. Oral route of peptide and protein drug delivery. In: Lee VH L. (ed.) Peptide and protein drug delivery. New York Marcel Dekker: 1991; 691 738
21. Werle M., Makhlof A., Takeuchi H. Oral protein delivery: A patent review of academic and industrial approaches. Recent Pat Drug Deliv Formul: 2009; 3 94 104
22. Woodley J. F. Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst: 1994; 11 61 95
23. Wacher V. J., Silverman J. A., Zhang Y. et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci: 1998; 87 1322 1330
24. Toorisaka E., Ono H., Arimori K. et al. Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oil-in-water (S/O/W) emulsion. Int J Pharm: 2003; 252 271 274
25. Niu M., Lu Y., Hovgaard L. et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: The effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm: 2012; 81 265 272
26. Lowman A. M., Morishita M., Kajita M. et al. Oral delivery of insulin using pH-responsive complexation gels. J Pharm Sci: 1999; 88 933 937
27. Liu X., Liu C., Zhang W. et al. Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin. Int J Pharm: 2013; 448 159 167
28. Agarwal V., Nazzal S., Reddy I. K. et al. Transport studies of insulin across rat jejunum in the presence of chicken and duck ovomucoids. J Pharm Pharmacol: 2001; 53 1131 1138
29. Brinckerhoff L. H., Kalashnikov V. V., Thompson L. W. et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines. Int J Cancer: 1999; 83 326 334
30. Kidron M., Dinh S., Menachem Y. et al. A novel per-oral insulin formulation: Proof of concept study in non-diabetic subjects. Diabet Med: 2004; 21 354 357
31. Bechara C., Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett: 2013; 587 1693 1702
32. Khafagy el-S, Morishita M. Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev: 2012; 64 531 539
33. Traverso G., Schoellhammer C. M., Schroeder A. et al. Microneedles for drug delivery via the gastrointestinal tract. J Pharm Sci: 2015; 104 362 367
34. www.emisphere.com [accessed October 2014]
35. Castelli M. C., Wong D. F., Friedman K. et al. Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): An open-label, randomized, single-dose, parallel-group study in healthy male subjects. Clin Ther: 2011; 33 934 945
36. Lee C. M., Chen C. Y., Chien R. N. et al. A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse. J Interferon Cytokine Res: 2014; 34 187 194
37. Bennett A. L., Smith D. W., Cummins M. J. et al. Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: A double-blind, parallel controlled trial during an influenza pandemic year. Influenza Other Respir Viruses: 2013; 7 854 862
38. http://www.bone-ltd.com [accessed October 2014]
39. Bone Ltd. Platform Technologies
40. http://www.merrionpharma.com [accessed October 2014]
41. http://www.oramed.com [accessed October 2014]
42. Eldor R., Kidron M., Arbi E. A Single-Blind, Two-Period Study to Assess the Safety and Pharmacodynamics of an Orally Delivered GLP-1 Analog (Exenatide) in Healthy Subjects. Poster presented at the 70th Scientific Sessions of the American Diabetes Association; June 25-29: 2010; Orlando, FL
43. http://enterisbiopharma.com [accessed October 2014]
44. Henriksen K., Andersen J. R., Riis B. J. et al. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Bone: 2013; 53 160 166
45. http://www.caratherapeutics.com [accessed October 2014]
46. http://www.chiasmapharma.com [accessed October 2014]
47. Tuvia S., Pelled D., Marom K. et al. A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms. Pharm Res: 2014; 31 2010 2021
48. European Medicines Agency Herceptin Summary of Product Characteristics. September: 2014
49. European Medicines Agency MabThera Summary of Product Characteristics. July: 2014
50. European Medicines Agency RoActemra Summary of Product Characteristics. September: 2014
51. European Medicines Agency Velcade Summary of Product Characteristics. April: 2014
52. Ismael G., Hegg R., Muehlbauer S. et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): A phase 3, open-label, multicentre randomised trial. Lancet Oncol: 2012; 13 869 878
53. Davies A., Merli F., Mihaljevic B. et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): Stage 1 analysis of a randomised phase 3 study. Lancet Oncol: 2014; 15 343 352
54. Burmester G. R., Rubbert-Roth A., Cantagrel A. et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis: 2014; 73 69 74
55. Ogata A., Tanimura K., Sugimoto T. et al. Musashi Study Investigators. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken): 2014; 66 344 354
56. Moreau P., Pylypenko H., Grosicki S. et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol: 2011; 12 431 440
57. European Medicines Agency Assessment report: Herceptin. June: 2013
58. European Medicines Agency Assessment report: MabThera. January: 2014
59. European Medicines Agency Assessment report: Velcade. June: 2012
60. European Medicines Agency Assessment report: RoActemra. February: 2014
61. Bookbinder L. H., Hofer A., Haller M. F. et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release: 2006; 114 230 241
62. Moreau P., Coiteux V., Hulin C. et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica: 2008; 93 1908 1911
63. Wynne C., Harvey V., Schwabe C. et al. Comparison of subcutaneous and intravenous administration of trastuzumab: A phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol: 2013; 53 192 201
64. Salar A., Avivi I., Bittner B. et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: Results from a two-stage, phase IB study. J Clin Oncol: 2014; 32 1782 1791
65. Zhang X., Chen Y. C., Fettner S. et al. Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther: 2013; 51 620 630
66. Zhang X., Georgy A., Rowell L. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int J Clin Pharmacol Ther: 2013; 51 443 455
67. http://clinicaltrials.gov/ct2/show/NCT01200758 [accessed October 2014]
68. Ohta S., Tsuru T., Terao K. et al. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol: 2014; 54 109 119
69. Morcos P. N., Zhang X., McIntyre C. et al. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. Int J Clin Pharmacol Ther: 2013; 51 537 548
70. Kivitz A., Olech E., Borofsky M. et al. Subcutaneous tocilizumab vs. placebo in combination with disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken): 2014; 66 1653 1661
71. Liang J. F., Yang V. C. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun: 2005; 335 734 738
72. Wang D. D., Zhang S., Zhao H. et al. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol: 2009; 49 1012 1024
73. Lui C. Y., Amidon G. L., Berardi R. R. et al. Comparison of gastrointestinal pH in dogs and humans: Implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci: 1986; 75 271 274
74. Musther H., Olivares-Morales A., Hatley O. J. et al. Animal versus human oral drug bioavailability: Do they correlate? Eur J Pharm Sci: 2014; 57 280 291
75. Akabane T., Tabata K., Kadono K. et al. A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos: 2010; 38 308 316
76. Parrott N., Lukacova V., Fraczkiewicz G. et al. Predicting pharmacokinetics of drugs using physiologically based modeling- A pplication to food effects. AAPS J: 2009; 11 45 53
77. Stroh M., Duda D. G., Takimoto C. H. et al. Translation of anticancer efficacy from nonclinical models to the clinic. CPT Pharmacometrics Syst Pharmacol: 2014; 3 e128
78. Tuvia S., Atsmon J., Teichman S. L. et al. Oral octreotide absorption in human subjects: Comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab: 2012; 97 2362 2369
79. Mao C. P., Brovarney M. R., Dabbagh K. et al. Subcutaneous versus intravenous administration of rituximab: Pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS One: 2013; 8 e80533